Cross protection against influenza A virus by yeast-expressed heterologous tandem repeat M2 extracellular proteins

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Lee, Yu Na ^a   Kim, Min Chul ^a,b   Lee, Young Tae ^a   Hwang, Hye Suk ^a   Lee, Jongsang ^c   Kim, Cheol ^c   Kang, Sang Moo ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b Animal Plant and Fisheries Quarantine and Inspection Agency   (South Korea)

^c BEAMS Biotechnology Co Ltd   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; FC RECEPTOR; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; M2E5X PROTEIN VACCINE; UNCLASSIFIED DRUG; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BONE MARROW DERIVED MACROPHAGE; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PROTECTION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; GENE EXPRESSION SYSTEM; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA A VIRUS; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA A VIRUS (H5N1); LUNG LAVAGE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; T LYMPHOCYTE; YEAST; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; CHICK EMBRYO; CROSS REACTION; DOG; GENETICS; IMMUNOLOGY; MDCK CELL LINE; METABOLISM; MOLECULAR GENETICS; ORTHOMYXOVIRIDAE INFECTIONS; PATHOGENICITY; PICHIA; TANDEM REPEAT; VIROLOGY;

AMINO ACID SEQUENCE; ANIMALS; CHICK EMBRYO; CROSS REACTIONS; DOGS; FEMALE; INFLUENZA A VIRUS; INFLUENZA VACCINES; MADIN DARBY CANINE KIDNEY CELLS; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; ORTHOMYXOVIRIDAE INFECTIONS; PICHIA; RECEPTORS, FC; RECOMBINANT PROTEINS; TANDEM REPEAT SEQUENCES; VIRAL MATRIX PROTEINS;

EID: 84945565558     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0137822     Document Type: Article

References (63)

1. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009; 361(20):1945-52. Epub 2009/09/12. NEJMoa0906453 [pii] doi: 10.1056/NEJMoa0906453 PMID: 19745214.
2. Lin YP, Shaw M, Gregory V, Cameron K, Lim W, Klimov A, et al. Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates. Proc Natl Acad Sci U S A. 2000; 97(17):9654-8. Epub 2000/08/02. doi: 10.1073/pnas.160270697 160270697 [pii]. PMID: 10920197; PubMed Central PMCID: PMC16920.
3. Husain M. Avian influenza A (H7N9) virus infection in humans: Epidemiology, evolution, and pathogenesis. Infect Genet Evol. 2014; 28C:304-12. Epub 2014/12/03. S1567-1348(14)00387-6 [pii] doi: 10. 1016/j.meegid.2014.10.016 PMID: 25446940.
4. Ito T, Gorman OT, Kawaoka Y, Bean WJ, Webster RG. Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J Virol. 1991; 65(10):5491-8. Epub 1991/10/01. PMID: 1895397.
5. Zebedee SL, Lamb RA. Nucleotide sequences of influenza A virus RNA segment 7: a comparison of five isolates. Nucleic Acids Res. 1989; 17(7):2870. Epub 1989/04/11. PMID: 2701939; PubMed Central PMCID: PMC317678.
6. Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W. A "universal" human influenza A vaccine. Virus Res. 2004; 103(1-2):173-6. PMID: 15163506.
7. Du L, Zhou Y, Jiang S. Research and development of universal influenza vaccines. Microbes Infect. 2010; 12(4):280-6. Epub 2010/01/19. S1286-4579(10)00003-1 [pii] doi: 10.1016/j.micinf.2010.01.001 PMID: 20079871.
8. Zhao G, Lin Y, Du L, Guan J, Sun S, Sui H, et al. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol J. 2010; 7:9. Epub 2010/ 01/20. 1743-422X-7-9 [pii] doi: 10.1186/1743-422X-7-9 PMID: 20082709; PubMed Central PMCID: PMC2823673.
9. Wong KK, Bulimo WD, Magana J, Achilla RA, Schwarcz SK, Simwa M, et al. Epidemiology of 2009 pandemic influenza A virus subtype H1N1 among Kenyans aged 2 months to 18 years, 2009-2010. J Infect Dis. 2012; 206 Suppl 1:S68-73. Epub 2012/11/28. jis585 [pii] doi: 10.1093/infdis/jis585 PMID: 23169975.
10. Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine. 2011; 29 (32):5145-52. Epub 2011/06/01. doi: 10.1016/j.vaccine.2011.05.041 PMID: 21624416.
11. Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis. 2007; 13(3):426-35. Epub 2007/06/08. PMID: 17552096.
12. Song JM, Van Rooijen N, Bozja J, Compans RW, Kang SM. Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc Natl Acad Sci U S A. 2011; 108 (2):757-61. Epub 2010/12/29. 1012199108 [pii] doi: 10.1073/pnas.1012199108 PMID: 21187388.
13. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med. 1999; 5(10):1157-63. PMID: 10502819.
14. Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine. 2008; 26(2):201-14. PMID: 18063235.
15. Fu TM, Grimm KM, Citron MP, Freed DC, Fan J, Keller PM, et al. Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine. 2009; 27(9):1440-7. Epub 2009/01/17. S0264-410X(08)01759-3 [pii] doi: 10. 1016/j.vaccine.2008.12.034 PMID: 19146898.
16. Ernst WA, Kim HJ, Tumpey TM, Jansen AD, Tai W, Cramer DV, et al. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine. 2006; 24(24):5158-68. PMID: 16713037.
17. Kim MC, Song JM, Ou E, Kwon YM, Lee YJ, Compans RW, et al. Virus-like Particles Containing Multiple M2 Extracellular Domains Confer Improved Cross-protection Against Various Subtypes of Influenza Virus. Molecular therapy: the journal of the American Society of Gene Therapy. 2013; 21(2):485-92. Epub 2012/12/19. doi: 10.1038/mt.2012.246 PMID: 23247101.
18. Sivakumar SM, Safhi MM, Kannadasan M, Sukumaran N. Vaccine adjuvants-Current status and prospects on controlled release adjuvancity. Saudi Pharm J. 2011; 19(4):197-206. Epub 2011/10/01. doi: 10.1016/j.jsps.2011.06.003 SPJ91 [pii]. PMID: 23960760; PubMed Central PMCID: PMC3744968.
19. Hilleman MR. Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine. 2000; 18(15):1436-47. Epub 2000/01/05. S0264410X9900434X [pii]. PMID: 10618541.
20. Shi L, Sings HL, Bryan JT, Wang B, Wang Y, Mach H, et al. GARDASIL: prophylactic human papillomavirus vaccine development-from bench top to bed-side. Clin Pharmacol Ther. 2007; 81(2):259-64. Epub 2007/01/30. 6100055 [pii] doi: 10.1038/sj.clpt.6100055 PMID: 17259949.
21. Boland G, Beran J, Lievens M, Sasadeusz J, Dentico P, Nothdurft H, et al. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine. 2004; 23(3):316-20. Epub 2004/11/09. S0264-410X(04)00471-2 [pii] doi: 10.1016/j.vaccine.2004.06.006 PMID: 15530674.
22. Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006; 24(33-34):5937-49. Epub 2006/07/11. S0264-410X(06)00709-2 [pii] doi: 10.1016/j.vaccine.2006.06.005 PMID: 16828940.
23. Song JM, Hossain J, Yoo DG, Lipatov AS, Davis CT, Quan FS, et al. Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology. 2010; 405(1):165-75. Epub 2010/06/29. S0042-6822(10)00378-8 [pii] doi: 10.1016/j.virol.2010.05.034 PMID: 20580392; PubMed Central PMCID: PMC2925114.
24. Quan FS, Compans RW, Nguyen HH, Kang SM. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol. 2008; 82(3):1350-9. PMID: 18032492.
25. Song JM, Wang BZ, Park KM, Van Rooijen N, Quan FS, Kim MC, et al. Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One. 2011; 6(1):e14538. Epub 2011/01/27. doi: 10.1371/journal.pone.0014538 PMID: 21267073; PubMed Central PMCID: PMC3022578.
26. Lee YN, Lee HJ, Lee DH, Kim JH, Park HM, Nahm SS, et al. Severe canine influenza in dogs correlates with hyperchemokinemia and high viral load. Virology. 2011; 417(1):57-63. Epub 2011/06/03. S0042- 6822(11)00218-2 [pii] doi: 10.1016/j.virol.2011.05.005 PMID: 21632085.
27. Quan FS, Kim YC, Yoo DG, Compans RW, Prausnitz MR, Kang SM. Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin. PLoS One. 2009; 4(9):e7152. Epub 2009/09/26. doi: 10.1371/journal.pone.0007152 PMID: 19779615; PubMed Central PMCID: PMC2745577.
28. Lee YN, Kim MC, Lee YT, Hwang HS, Cho MK, Lee JS, et al. AS04-adjuvanted virus-like particles containing multiple M2 extracellular domains of influenza virus confer improved protection. Vaccine. 2014; 32(35):4578-85. Epub 2014/06/22. S0264-410X(14)00829-9 [pii] doi: 10.1016/j.vaccine.2014.06.040 PMID: 24951867; PubMed Central PMCID: PMC4126506.
29. Kim MC, Lee JS, Kwon YM, Ou E, Lee YJ, Choi JG, et al. Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection. Antiviral Res. 2013; 99(3):328-35. Epub 2013/07/03. S0166-3542(13)00167-8 [pii] doi: 10. 1016/j.antiviral.2013.06.010 PMID: 23811283; PubMed Central PMCID: PMC3788098.
30. Kim MC, Lee YN, Ko EJ, Lee JS, Kwon YM, Hwang HS, et al. Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity and provides long-term cross protection. Mol Ther. 2014; 22(7):1364-74. Epub 2014/03/05. mt201433 [pii] doi: 10.1038/mt.2014.33 PMID: 24590045; PubMed Central PMCID: PMC4089011.
31. De Filette M, Martens W, Roose K, Deroo T, Vervalle F, Bentahir M, et al. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem. 2008; 283(17):11382-7. Epub 2008/02/07. M800650200 [pii] doi: 10.1074/jbc.M800650200 PMID: 18252707; PubMed Central PMCID: PMC2431085.
32. Treanor JJ, Tierney EL, Zebedee SL, Lamb RA, Murphy BR. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol. 1990; 64(3):1375-7. Epub 1990/03/01. PMID: 2304147; PubMed Central PMCID: PMC249260.
33. Zharikova D, Mozdzanowska K, Feng J, Zhang M, Gerhard W. Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2. J Virol. 2005; 79 (11):6644-54. Epub 2005/05/14. 79/11/6644 [pii] doi: 10.1128/JVI.79.11.6644-6654.2005 PMID: 15890902; PubMed Central PMCID: PMC1112148.
34. Hashimoto Y, Moki T, Takizawa T, Shiratsuchi A, Nakanishi Y. Evidence for phagocytosis of influenza virus-infected, apoptotic cells by neutrophils and macrophages in mice. J Immunol. 2007; 178(4):2448-57. Epub 2007/02/06. 178/4/2448 [pii]. PMID: 17277152.
35. Lee YN, Lee YT, Kim MC, Hwang HS, Lee JS, Kim KH, et al. Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M2 vaccination. Immunology. 2014; 143(2):300-9. Epub 2014/04/30. doi: 10.1111/imm.12310 PMID: 24773389.
36. Kim MC, Song JM, Ou E, Kwon YM, Lee YJ, Compans RW, et al. Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther. 2013; 21(2):485-92. Epub 2012/12/19. mt2012246 [pii] doi: 10.1038/mt.2012.246 PMID: 23247101; PubMed Central PMCID: PMC3594028.
37. El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, Birkett A, et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol. 2011; 186(2):1022-31. Epub 2010/12/21. jimmunol.0902147 [pii] doi: 10.4049/ jimmunol.0902147 PMID: 21169548.
38. Liu W, Zou P, Ding J, Lu Y, Chen YH. Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. Microbes Infect. 2005; 7(2):171-7. Epub 2005/03/22. S1286-4579(04)00349-1 [pii] doi: 10. 1016/j.micinf.2004.10.006 PMID: 15777646.
39. Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine. 2004; 22(23- 24):2993-3003. Epub 2004/08/07. doi: 10.1016/j.vaccine.2004.02.021 S0264410X04001835 [pii]. PMID: 15297047.
40. Krammer F, Grabherr R. Alternative influenza vaccines made by insect cells. Trends Mol Med. 2010; 16(7):313-20. Epub 2010/06/24. S1471-4914(10)00071-7 [pii] doi: 10.1016/j.molmed.2010.05.002 PMID: 20570562.
41. Krammer F, Schinko T, Palmberger D, Tauer C, Messner P, Grabherr R. Trichoplusia ni cells (High Five) are highly efficient for the production of influenza A virus-like particles: a comparison of two insect cell lines as production platforms for influenza vaccines. Mol Biotechnol. 2010; 45(3):226-34. Epub 2010/03/20. doi: 10.1007/s12033-010-9268-3 PMID: 20300881; PubMed Central PMCID: PMC4388404.
42. Haynes JR, Dokken L, Wiley JA, Cawthon AG, Bigger J, Harmsen AG, et al. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine. 2009; 27(4):530-41. Epub 2008/11/26. S0264-410X(08)01521-1 [pii] doi: 10.1016/ j.vaccine.2008.11.011 PMID: 19026705.
43. Margine I, Martinez-Gil L, Chou YY, Krammer F. Residual baculovirus in insect cell-derived influenza virus-like particle preparations enhances immunogenicity. PLoS One. 2012; 7(12):e51559. Epub 2012/ 12/14. doi: 10.1371/journal.pone.0051559 PONE-D-12-25207 [pii]. PMID: 23236516; PubMed Central PMCID: PMC3517492.
44. Cox MM, Hollister JR. FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals. 2009; 37(3):182-9. Epub 2009/03/20. S1045-1056(09)00028-1 [pii] doi: 10.1016/j.biologicals. 2009.02.014 PMID: 19297194.
45. Liu W, Peng Z, Liu Z, Lu Y, Ding J, Chen YH. High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity. Vaccine. 2004; 23(3):366-71. PMID: 15530682.
46. Heinen PP, Rijsewijk FA, de Boer-Luijtze EA, Bianchi AT. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J Gen Virol. 2002; 83(Pt 8):1851-9. Epub 2002/07/19. PMID: 12124449.
47. De Filette M, Ramne A, Birkett A, Lycke N, Lowenadler B, Min Jou W, et al. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine. 2006; 24(5):544-51. Epub 2005/09/20. S0264-410X(05)00878-9 [pii] doi: 10.1016/ j.vaccine.2005.08.061 PMID: 16169634.
48. Andersson AM, Hakansson KO, Jensen BA, Christensen D, Andersen P, Thomsen AR, et al. Increased immunogenicity and protective efficacy of influenza M2e fused to a tetramerizing protein. PLoS One. 2012; 7(10):e46395. Epub 2012/10/11. doi: 10.1371/journal.pone.0046395 PONE-D-12-18547 [pii]. PMID: 23049700; PubMed Central PMCID: PMC3462204.
49. Garcon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines. 2007; 6(5):723-39. Epub 2007/10/13. doi: 10. 1586/14760584.6.5.723 PMID: 17931153.
50. King C, Tangye SG, Mackay CR. T follicular helper (TFH) cells in normal and dysregulated immune responses. Annu Rev Immunol. 2008; 26:741-66. Epub 2008/01/05. doi: 10.1146/annurev.immunol. 26.021607.090344 PMID: 18173374.
51. Fazilleau N, McHeyzer-Williams LJ, Rosen H, McHeyzer-Williams MG. The function of follicular helper T cells is regulated by the strength of T cell antigen receptor binding. Nat Immunol. 2009; 10(4):375-84. Epub 2009/03/03. ni.1704 [pii] doi: 10.1038/ni.1704 PMID: 19252493; PubMed Central PMCID: PMC2712297.
52. Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci. 2008; 65(20):3231-40. Epub 2008/08/01. doi: 10.1007/s00018- 008-8228-6 PMID: 18668203; PubMed Central PMCID: PMC2647720.
53. MacLeod MK, McKee AS, David A, Wang J, Mason R, Kappler JW, et al. Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells. Proc Natl Acad Sci U S A. 2011; 108(19):7914-9. Epub 2011/04/27. 1104588108 [pii] doi: 10. 1073/pnas.1104588108 PMID: 21518876; PubMed Central PMCID: PMC3093483.
54. Shim BS, Choi YK, Yun CH, Lee EG, Jeon YS, Park SM, et al. Sublingual Immunization with M2-Based Vaccine Induces Broad Protective Immunity against Influenza. PLoS One. 2011;6(11). ARTN e27953 doi: 10.1371/journal.pone.0027953. ISI:000298168100027.
55. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol. 2004; 172 (9):5598-605. Epub 2004/04/22. PMID: 15100303.
56. Kim EH, Lee JH, Pascua PN, Song MS, Baek YH, Kwon HI, et al. Prokaryote-expressed M2e protein improves H9N2 influenza vaccine efficacy and protection against lethal influenza A virus in mice. Virol J. 2013; 10:104. Epub 2013/04/05. 1743-422X-10-104 [pii] doi: 10.1186/1743-422X-10-104 PMID: 23551908; PubMed Central PMCID: PMC3621599.
57. Park JK, Lee DH, Cho CH, Yuk SS, To EO, Kwon JH, et al. Supplementation of oil-based inactivated H9N2 vaccine with M2e antigen enhances resistance against heterologous H9N2 avian influenza virus infection. Vet Microbiol. 2014; 169(3-4):211-7. Epub 2014/01/30. S0378-1135(14)00017-0 [pii] doi: 10. 1016/j.vetmic.2014.01.001 PMID: 24472228.
58. Talbot HK, Rock MT, Johnson C, Tussey L, Kavita U, Shanker A, et al. Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin. PLoS One. 2010; 5(12):e14442. Epub 2011/01/05. doi: 10.1371/journal.pone.0014442 PMID: 21203437; PubMed Central PMCID: PMC3010987.
59. Eliasson DG, El Bakkouri K, Schon K, Ramne A, Festjens E, Lowenadler B, et al. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine. 2008; 26(9):1243-52. Epub 2008/02/05. S0264-410X(07)01495-8 [pii] doi: 10.1016/j.vaccine.2007.12.027 PMID: 18243429.
60. Chung EY, Kim SJ, Ma XJ. Regulation of cytokine production during phagocytosis of apoptotic cells. Cell Res. 2006; 16(2):154-61. Epub 2006/02/14. 7310021 [pii] doi: 10.1038/sj.cr.7310021 PMID: 16474428.
61. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood. 2012; 119(24):5640-9. Epub 2012/04/27. blood-2012-01-380121 [pii] doi: 10.1182/blood-2012- 01-380121 PMID: 22535666.
62. Daeron M. Fc receptor biology. Annu Rev Immunol. 1997; 15:203-34. Epub 1997/01/01. doi: 10.1146/ annurev.immunol.15.1.203 PMID: 9143687.
63. Mancardi DA, Iannascoli B, Hoos S, England P, Daeron M, Bruhns P. FcgammaRIV is a mouse IgE receptor that resembles macrophage FcepsilonRI in humans and promotes IgE-induced lung inflammation. J Clin Invest. 2008; 118(11):3738-50. Epub 2008/10/25. doi: 10.1172/JCI36452 PMID: 18949059; PubMed Central PMCID: PMC2571035.